Adventrx Pharmaceuticals Inc. (AMEX: ANX)

Adventrx Pharmaceuticals Inc. (ANX) engages in the in-licensing, development and commercialization of cancer-related proprietary drug therapies. The Company seeks to improve upon existing treatments of cancer.

Founded in 1995, the Company is headquartered in San Diego, California.

Source: Reuters.com, SEC Filings.

Financial Summary

Source: Reuters.com, SEC Filings.

Analyst Consensus

No analyst polled by Thomson Reuters rates shares of ANX at this time.

Investment Highlights

According to the Cancer Market Outlook report published by Business Insights, the market for cancer therapeutic drugs is expected to reach $40.9 billion by 2012. If approved by the U.S. Food and Drug Administration (FDA), the market for the Company’s drug candidates has a potential to reach more than $1.0 billion at market saturation.

Pharmaceutical companies with revenue of more than $1 billion include Cephalon Inc. (Nasdaq: CEPH), which trades at a market capitalization of $4.73 billion, and King Pharmaceuticals (Nasdaq: KG), which trades at a market capitalization of $3.15 billion. As of January 6, ANX trades at a market capitalization of $50.7 million.

The Company is in the process of commercializing two drug-therapy candidates in late stages of Food and Drug administration (FDA) clinical trials in the United States. The Company’s two candidates include ANX-530 (vinorelbine emulsion) and ANX-514 (docetaxel emulsion), formulated to enhance certain standard-of-care chemotherapy drugs. The Company also states that ANX-530 and ANX-514 are safer, more convenient and less expensive than Navelbine and Taxotere, two drug therapies currently marketed.

The Company’s strategy is to take advantage of an effective lifecycle-management technique of reformulating existing successfully marketed drug therapies. Of the top 50 pharmaceutical companies, more than 40% of all drug therapies produced have been reformulated to extend the life of existing marketed drugs between the years 2002 and 2005. Patent expirations and competition are threats to all pharmaceutical companies. Modified and improved existing products have become an important technique as a method of improving revenue stream for longer time periods.

The Company believes that chemotherapy drugs Navelbine and Taxotere have limitations that can be improved upon with its novel technologies. A new formulation of these two popular standard-of-care drug therapies is expected to reduce side-effects, negative results and medical complications of patients suffering from cancer.

The Company has attracted capital from Icahn Capital Management, Carl Icahn (as an individual), Barclays Global Investors UK Holdings, Vanguard Group among other well-know investors and group holding companies.

Recent Company News

On January 6, the Company announced that it will present at the OneMedForum Finance Conference at the Sir Francis Drake Hotel in San Francisco on January 13, 2010.

Technical Analysis

Source: http://stockcharts.com/h-sc/ui?s=ANX

ANX trades above its 13-day moving average. This bullish sign is significant because the 13-day moving average is upwardly sloped.

The MACD for ANX currently indicates a bullish signal. The MACD is above the signal line, a 9-day moving average of the MACD. The MACD is above the critical level of 0, which implies the past price action had been positive. Overall, the chart is bullish.

Comparative Analysis

Source: Thomson Financial

Insider Trading Activity

Source: Yahoo Finance

Report Disclaimer

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.